Article images may contain Chinese text.
Weiming Penguin Was Invited to the 2025 CIAPH Pharmaceutical and Healthcare Industry Digitalization Summit
Weiming Penguin Co-founder and President Tian Ying Attended with the Team
At the Forefront of the Industry: A Shared Mission as a Vice President Member Organization
On March 13, Weiming Penguin, a vice president member organization of the China Association of Pharmaceutical Commerce, was invited to attend the 13th CIAPH Pharmaceutical and Healthcare Industry Digitalization Summit. Bringing together more than 200 leading companies, including Novartis, Tasly, and China Resources, the event centered on “Digital Intelligence: Strengthening Pharmaceutical Company Resilience,” strongly resonating with Weiming Penguin's decade-long strategy of “driving industry upgrades through data.” As an association leader emphasized in an address, “Digitalization is not an optional question; it is one that pharmaceutical companies must answer to navigate market cycles.” As an ongoing strategic partner of the forum, Weiming Penguin once again demonstrated the responsibility expected of an industry leader.
DeepSeek: Unlocking Growth Through Outlet InsightsAt this forum, Weiming Penguin publicly unveiled its flagship 2025 product, “DeepSeek Outlet Insights Expert,” for the first time. Built on hundreds of millions of outlet-related performance data records accumulated over ten years and integrated with large AI models, the solution demonstrated three core areas of value on site:
▶ Data foundation: Connecting end-to-end data across pharmaceutical companies, distributors, and outlets to build a dynamic “digital twin” market. A case involving a top 10 pharmaceutical company showed a 40% improvement in outlet coverage accuracy;
▶ Decision support: Using AI clustering to analyze profiles of more than 300,000 retail stores and automatically generate targeted distribution plans for county-level markets. Following a pilot at an OTC company, outlet sell-through rates increased by 28%;
▶ Compliance safeguards: Built-in data masking and tiered access controls comply with the latest Guidelines for Pharmaceutical Data Security and Compliance, attracting several pharmaceutical companies to in-depth discussions on “compliant data sharing” at the event.
The DIG Portfolio: End-to-End Enablement from Data to Value
At the session on “Putting Digital Intelligence Use Cases into Practice,” Weiming Penguin's DIG portfolio of intelligent digitalization solutions sparked lively discussion:
• Master data management platform: Helped a leading pharmaceutical company standardize more than 800,000 customers and over 20,000 related SKUs, improving supply chain collaboration efficiency by 35%;
• Territory management tool: Used AI algorithms to optimize visit routes for 300,000 primary care institutions. An on-site estimate by a medical device company representative put annual costs for a single province at 1.2 million;
• Patient insights system: The 2025 Report on Hypertension Medication Trends, generated from real-world diagnosis and treatment data, became an important reference for several pharmaceutical companies adjusting their R&D pipelines.
Notably, the booth featured an interactive “Primary Healthcare Digitalization” display simulating how a county-level medical community used Weiming Penguin's system to increase access to medicines in primary care from 38% to 62%—closely aligning with the national strategy of “extending medical resources to the grassroots” discussed at China's 2025 Two Sessions.
A Dialogue on the Future: Making the Value of Technology Tangible and Approachable
During the forum, the Weiming Penguin team held in-depth discussions with more than 100 customers. The CIO of one pharmaceutical manufacturer praised the company on site: “Penguin AI's ‘automated intelligent pricing’ feature increased our O2O sales by 30% in some of the regions covered by our collaboration. This is truly down-to-earth digitalization.” This implementation mindset of “technology + use cases” addresses real challenges involving dynamic inventory and efficient supply chains and runs through all of Weiming Penguin's solutions. As the company's Chief Data Officer said during the roundtable, “Pharmaceutical digitalization is not about showing off technology. It is about helping every pill reach someone who needs it and ensuring every piece of data creates real value.”
Charting the Course: Moving Toward Digital Intelligence with the IndustryAs the Two Sessions debated the boundaries of “AI + the healthcare industry,” Weiming Penguin demonstrated through practice that the ultimate goal of digitalization is to strengthen the industry's resilience in serving people's well-being. From helping pharmaceutical companies reduce marketing costs by 20% to improving the efficiency of primary care diagnosis and treatment, we have consistently upheld the principle that “data should have a human touch, and technology should be ethical”—all AI models follow legal requirements, and all data applications strictly comply with China's Personal Information Protection Law.
China's 2025 Government Work Report sets out a national direction of “artificial intelligence + medical care and health,”
Weiming Penguin will continue to advance through the twin drivers of a “data foundation + intelligent applications,” working with industry chain partners to make pharmaceutical digitalization not only more advanced, but also more human-centered.
Concluding Thoughts on the Pharmaceutical and Healthcare Digitalization Summit
As the “digital capsule” on the forum poster suggests:
When code meets medicine, technology ultimately returns to reverence and care for life.
